Seven in ten biologic-eligible asthma patients improved without a biologic

Design

Nationwide retrospective cohort from UK electronic records with trajectory clustering

Population

10,078 biologic-naive adults meeting biologic criteria for severe asthma

Primary outcome

Exacerbation trajectories after first eligibility

Effect

Remitting 70%, chronic-frequent 20%, refractory 10%; eosinophils 0.30 vs 0.23 × 10⁹/L

UK primary care records identified 10,078 biologic-naive adults in the first year they met severe asthma criteria with three or more steroid-treated exacerbations — the usual threshold for a biologic. Researchers then traced what happened over the following years without biologic treatment.

Three patterns emerged. Seventy per cent improved to fewer than three exacerbations a year and stayed there, even as inhaled steroid doses fell. Twenty per cent kept exacerbating frequently, a median of five a year. Ten per cent needed more than ten steroid courses a year. The persistently frequent group had higher blood eosinophils (median 0.30 × 10⁹/L) — and this was visible several years before they became eligible.

This matters for interpreting improvement after a biologic is started: much of it may be regression to the mean. It is observational data from health records, so it cannot say who would have benefited from a biologic, but it suggests that a single bad year is a weak basis for lifelong treatment, and that eosinophil history helps identify those who will stay unwell.

• Recheck adherence, inhaler technique and triggers after a bad year before starting a biologic
• Review blood eosinophil counts over previous years, not only the most recent result
• Prioritise biologics for patients with persistent exacerbations and raised eosinophils
• Reassess benefit after a biologic is started, remembering that many patients improve anyway

Why it matters

It challenges the assumption that improvement after starting a biologic is always due to the drug.

Don't overread it

This describes natural history in records; it does not show that biologics would not have helped the improving group.

The statistics, in plain English

The trajectories were grouped by a clustering method that looks for common patterns over time. Their consistency across sensitivity analyses makes them more credible, but the groups are descriptive, not tested treatments.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.